NasdaqCM:LQDAPharmaceuticals
73% Below Fair Value As Liquidia (LQDA) Shifts Toward Commercialization?
Liquidia stock reacts to shift toward commercialization
Liquidia (LQDA) moved back into focus after investors responded to its transition toward a commercial-stage model, with updated earnings and sales projections for lead therapy YUTREPIA and heavier trading activity drawing fresh attention to the stock.
See our latest analysis for Liquidia.
At a share price of US$78.17, Liquidia has seen strong momentum, with a 30 day share price return of 26.02% and a 90 day gain of 123.15%. The 1 year...